GIP

Brookfield and GIP are proceeding with a $7.5 billion deal in Kuwait despite ongoing war conditions. The deal involves Kuwait Petroleum Corp., led by Sheikh Nawaf Al-Sabah.

A new triple-action weekly jab for type 2 diabetes, retatrutide, showed significant reductions in blood sugar and body weight in phase 3 trials. Patients receiving retatrutide lost over four times more weight and experienced more than twice the drop in HbA1c compared to placebo. The drug mimics three gut hormones (GLP-1, GIP, and glucagon) and differs from existing diabetes medications by engaging the glucagon receptor to increase energy expenditure.

Eli Lilly has developed an experimental weight loss injection that achieved 28% weight loss in trials. The new shot differs from existing medications Zepbound and Foundayo by combining three active components: GIP, GLP-1, and glucagon.

Abu Dhabi's L'imad is planning a $30 billion infrastructure push in collaboration with Temasek and GIP. This investment aims to boost development in the region. The project involves residential high-rise buildings in Abu Dhabi.

Researchers have created a new obesity drug that uses GLP-1/GIP signals to target cells and enhance metabolism, outperforming existing treatments in mice by curbing appetite and improving blood sugar levels. The drug can be used at lower doses, potentially reducing side effects. It shows promise for effective weight loss.